2 registrations that name equol as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
2US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 2 registrations
RecruitingNCT07194590
Equol and Vascular Function in Women With Chronic Kidney Disease
Phase 2
University of Colorado, Denver
About 74 people
Started Feb 19, 2026
In plain words A Phase 2 study of equol in female participants 50 and older, run by University of Colorado, Denver. It plans to enroll about 74 people at 1 US site.
CKD stage 3 or 4 (eGFR with the CKD-EPI 2021 race-free equation: 15-59 mL/min/1.73m2; stable renal function in the past 3 months)
Low habitual intake of soy (soy-related food intake < 2 times per week assessed by Soy-Specific Food Frequency Questionnaire)
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Equol; Placebo
Registered summary
The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06128278
Acute Equol Supplementation and Vascular Function in Women With and Without CKD
Phase 2
University of Colorado, Denver
About 38 people
Started Mar 7, 2023
In plain words A Phase 2 study of equol in female participants 50 to 69, run by University of Colorado, Denver. It plans to enroll about 38 people at 1 US site.
Women with CKD including stage 3-4 (eGFR 15-59 ml/min/1.73m2) determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 equation
Women without CKD (eGFR >60 ml/min/1.73m2) must be healthy (free from hypertension, kidney disease, CVD, diabetes, and other chronic disease as assessed by self-report, medical history, and screening labs).
The exclusion criteria are on the listing.
What it tests, as registered
S-equol; Placebo
Registered summary
The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH. The full summary is on the listing.